ABSTRACT
Klebsiella pneumoniae carbapenemase (KPC)-type enzymes were fi rst reported in carbapenem-resistant K. pneumoniae strains in North Carolina, United States (1) . Until 2005, the geographical distribution of these enzymes in members of the family Enterobacteriaceae -K. pneumoniae, in particular -was limited to the eastern part of the United States. In Brazil, KPC has been described since 2006, and it was fi rst reported in K. pneumoniae isolates from Recife (2) , followed by reports (3) in other species from the Enterobacteriaceae and non-fermenting bacilli (4) (5) (6) . Carbapenem resistance in Proteus mirabilis caused by KPC-2 was also fi rst reported in the United States (7) in 2008, and currently, there are a few reports of P. mirabilis KPC producers worldwide (8) (9) . The present report describes the detection of bla KPC-2 in P. mirabilis strains in Brazil for the fi rst time.
In May 2012, an isolate of Proteus mirabilis was recovered from the blood culture of a patient admitted to the intensive care unit of a tertiary hospital located in Recife, Pernambuco, Brazil. Biochemical identifi cation and determination of minimum inhibitory concentrations (MICs) of the isolate were performed using the BD Phoenix TM Automated Microbiology System, Franklin Lakes, New Jersey, USA and the susceptibility profi le was determined according to the guidelines of the Clinical and Laboratory Standards Institute (2013). The isolate was characterized as multidrug resistant, showing resistance to amikacin (MIC>32µg/mL), amoxicillin/clavulanate (MIC>16µg/mL), ampicillin (MIC>16µg/mL), cefazolin (MIC>16µg/mL), cefepime (MIC>16µg/mL), cefotaxime (MIC>32µg/mL), cefoxitin (MIC=16µg/mL), ceftriaxone (MIC>32µg/mL), ciprofl oxacin (MIC>2µg/mL), ertapenem (MIC>4µg/mL), imipenem (MIC>8µg/mL), gentamicin (MIC>8µg/mL), levofl oxacin (MIC>4µg/mL), piperacillin/ tazobactam (MIC>64µg/mL), and tobramycin (MIC>8µg/mL). It was susceptible only to meropenem, polymyxin, and tigecycline. Plasmid DNA was extracted by the UltraClean Endotoxin-Free Mini Plasmid Prep Kit (Mo Bio Lab, Carlsbad, CA, USA) and was visualized and analyzed by electrophoresis on a 0.7% agarose gel. The molecular weight of each plasmid was determined by comparison with plasmids of known molecular weight, e.g., with that of K. pneumoniae K16-P strain (3) . Five plasmids with estimated molecular sizes of >150kb, 150kb, 120kb, 90kb, and 70kb were identifi ed in the isolate. Genes bla KPC, bla VIM, bla IMP, bla SPM , bla GES , bla SHV , bla TEM , and bla CTX-M were analyzed by PCR using genomic DNA and specific primers (3) . bla VIM , bla IMP , bla SPM , bla GES , bla CTM-M , and bla SHV were not present, while bla KPC and bla TEM were detected, amplifying fragments of approximately 1,000bp . An additional PCR using plasmid DNA for bla KPC detection was performed to confi rm the plasmid origin of this gene. The coding regions of bla KPC and bla TEM were sequenced, and the analysis of the nucleotide sequences and deduced protein sequences with BLAST (http:// blast.ncbi.nlm.nih.gov/Blast.cgi) and EXPASY (http://web. expasy.org/tools/ translate) showed that the isolate harbored bla KPC-2 and bla TEM-1 (GenBank accession numbers KC736925 and KF811201). bla TEM has been described in P. mirabilis from Brazil by Dropa et al. (10) and Abreu et al. (11) , but they did not sequence the gene. The analysis of antimicrobial agents revealed susceptibility to meropenem, polymyxin, and tigecycline. Tibbetts et al. (7) identifi ed KPC-producing Proteus mirabilis isolates
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that were susceptible only to piperacillin/tazobactam and ciprofl oxacin in USA, and Sheng et al. (8) identifi ed a panresistant KPC-producing P. mirabilis isolate in China. According to Castanheira et al. (12) , meropenem, ceftazidime-avibactam, and tigecycline were the most active antimicrobials against the KPCproducing Escherichia coli, K. pneumoniae, Klebsiella oxytoca, and P. mirabilis isolates collected in 2012 from the all United States Census Bureau-designated regions. The identifi cation of bla KPC-2 as the underlying basis of carbapenem resistance in P. mirabilis isolates is worrisome, although this fi nding is not totally unexpected, given the recent documented spread of bla KPC carbapenemase to a number of gram-negative bacteria (4) (5) (13) (14) , including in K. pneumoniae and Pseudomonas aeruginosa in the same hospital in Recife, Brazil (3) (6) . These data indicate the intra-bacterial transference of bla KPC-2 at this hospital. According to the literature, bla KPC is encoded by transposon Tn4401, found in a variety of transferable plasmids (2) (15) . In this study, PCR experiments using plasmid DNA confi rmed that bla KPC-2 was present in the plasmids. Considering that transposons are mobile genetic elements, bla KPC-2 could be present in any of the 5 plasmids detected (>150 kb, 150kb, 120kb, 90kb, and 70kb). The data presented herein confi rm that P. mirabilis strains harboring bla KPC-2 are emerging in Brazil, suggesting the continuous transfer of bla KPC between bacterial genera. This poses a serious challenge to prevent infections caused by multidrug-resistant bacteria.
